Aligos Therapeutics, Inc. announced the appointment of James Hassard, MBA as Executive Vice President, Chief Commercial Officer, effective January 13, 2026. Mr. Hassard will lead and build the Company?s global commercial capabilities and serve as a member of Aligos? Senior Leadership Team.
Mr. Hassard is a seasoned executive with extensive experience building commercial organizations across multiple therapeutic areas. Prior to joining Aligos, Jim was Chief Commercial Officer at Crinetics Pharmaceuticals and Arrowhead Pharmaceuticals where he built the commercial capabilities and launch strategies for more than four rare disease programs. Earlier in his career, Mr. Hassard held positions of increasing responsibility at Coherus Oncology, Amgen, and Merck, launching multiple pharmaceutical products in therapeutic areas including hepatitis, oncology, and nephrology. He has global experience in the United States, Canada and Europe, including as general manager of Amgen Portugal.
Mr. Hassard earned a Bachelor of Science in Pharmacology from the University of Toronto, followed by a Master?s in Business Administration from Nova Southeastern University.
